Journal
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
Volume 82, Issue 1, Pages 43-48Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejpb.2012.06.002
Keywords
Enzymosome; Catalytic activity; Pharmacological characteristics; Uricase from Bacillus fastidious; In vitro
Categories
Funding
- National Natural Science Foundation of China [30973645]
- Chongqing Natural Science Foundation [cstc2012jjB10027]
- Specialized Research Fund for the Doctoral Program of Higher Education [20095503120008]
- Chongqing Education Committee Fund
Ask authors/readers for more resources
The aim of this study was to assess the potential of a novel alkaline enzymosome to deliver uricase from Bacillus fastidious (UBF) and enhance its biochemical and pharmacological characteristics. The in vitro catalytic activity of the UBF loaded in the novel alkaline enzymosomes (ESUBFs) was almost 3.8 times that of free UBF at the optimum pH or 1.5 times that of free UBF at the physiological pH. Following intravenous (i.v.) administration (2000 mU/kg) in rats, ESUBFs provided significantly higher (22.5-fold) area under the plasma concentration (AUC) and longer (8.2-fold) circulation half-life (t(1/2)) compared with free UBF, respectively. Further, it took only 4.5 h (or 1.1 h) for ESUBFs to lower the plasma uric acid concentration from a high level to the normal level of rat (or human beings), compared with 7.6 h (or 5.4 h) for free UBF. Our results showed that ESUBFs could efficiently deliver UBF and favorably modify its biochemical and pharmacological characteristics by increasing the AUC, t(1/2), and catalytic activity. Therefore, ESUBFs might be a preferred alternative to cure hyperuricemia and gout. (c) 2012 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available